Projects per year
Fingerprint
Dive into the research topics where Iris Dirven is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
-
AIIFUND147: Visiting Research Agreement Melanoma Therapies
Neyns, B. (Administrative Promotor) & Dirven, I. (PI (Promotor, Principal Investigator))
1/05/25 → 30/06/25
Project: Fundamental
-
A randomized phase II clinical trial on intratumoral autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) plus ipilimumab (IPI) and synthetic adjuvant AS01B combined with low-dose intravenous (IV) nivolumab (NIVO) in advanced pretreated melanoma patients.
Bertels, C., Dirven, I., Vounckx, M., Van Riet, I., De Becker, A. & Neyns, B., 1 Jun 2026, In: Journal of Clinical Oncology. 44, p. 21514-21514 1 p.Research output: Contribution to journal › Meeting abstract (Journal)
-
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases
Mandalà, M., Chen, M. F., Sullivan, R. J., Sergi, M. C., Postow, M., Lawless, A. R., Effiom, D., Peres, T., Lorigan, P. C., Serra-Bellver, P., Dummer, R., Amaral, T., Rasch, M.-L., Giannarelli, D., Vitale, M. G., Helgadottir, H., Robert, C., Ubaldi, M., Johnson, D. B. & Del Vecchio, M. & 25 others, , 4 May 2026, In: Journal for ImmunoTherapy of Cancer. 14, 5, 12 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial
Dirven, I., Bertels, C., Moreels, Y., Kessels, J. I., Vanlaer, N., Vander Mijnsbrugge, A.-S., Vounckx, M., Dirks, I., Raes, L., Geeraerts, X., Stevens, L., von Kemp, B., Fasolino, G., Awada, G., Janssen, T., Caljon, B., Lefevre, T., Everaert, H., Rogiers, A. & Vandemeulebroucke, J. & 2 others, , Apr 2026, In: ESMO Open. 11, 4, 11 p., 106941.Research output: Contribution to journal › Article › peer-review
Open Access -
Erratum to: Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma
Duerinck, J., Lescrauwaet, L. & Dirven, I., 1 Apr 2026, In: Neuro-oncology. 28, 4, p. e2-e2 1 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrative Review
Vounckx, M., Dirven, I., Bertels, C., Schwarze, J. K., Geeraerts, X., Tuyaerts, S., Boisson, A., Willard-Gallo, K. & Neyns, B., 30 Apr 2026, In: Vaccines. 14, 5, 15 p., 402.Research output: Contribution to journal › Scientific review › peer-review
Open Access
Prizes
Activities
-
Management of patients with melanoma central nervous system metastases
Dirven, I. (Speaker)
18 Oct 2025Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma (NEO-GLITIPNI).
Dirven, I. (Speaker)
31 May 2025Activity: Talk or presentation › Talk or presentation at a conference
-
2025 ASCO Annual Meeting
Aspeslagh, S. (Participant), Cleo, B. (Participant), Dirven, I. (Participant) & Decoster, L. (Participant)
30 May 2025 → 3 Jun 2025Activity: Participating in or organising an event › Participation in conference
-
Melanoma treatment Anno 2024
Dirven, I. (Speaker)
9 Mar 2024Activity: Talk or presentation › Talk at a public lecture/debate
-
A phase 2 clinical trial of regorafenib in patients with advanced pretreated melanoma (RegoMel).
Dirven, I. (Speaker)
1 Jun 2024Activity: Talk or presentation › Talk or presentation at a conference